stoxline Quote Chart Rank Option Currency Glossary
  
Simulations Plus, Inc. (SLP)
41.35  0.29 (0.71%)    03-27 16:00
Open: 41.6
High: 41.93
Volume: 55,620
  
Pre. Close: 41.06
Low: 41.2
Market Cap: 826(M)
Technical analysis
2024-03-28 8:17:38 AM
Short term     
Mid term     
Targets 6-month :  50.49 1-year :  52.5
Resists First :  43.23 Second :  44.95
Pivot price 42.87
Supports First :  40.45 Second :  33.65
MAs MA(5) :  42.34 MA(20) :  42.73
MA(100) :  40.48 MA(250) :  42.43
MACD MACD :  0.1 Signal :  0.4
%K %D K(14,3) :  9.4 D(3) :  26.1
RSI RSI(14): 45.6
52-week High :  52.68 Low :  32.68
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ SLP ] has closed above bottom band by 13.5%. Bollinger Bands are 29.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 41.95 - 42.2 42.2 - 42.45
Low: 40.6 - 40.9 40.9 - 41.18
Close: 40.9 - 41.33 41.33 - 41.75
Company Description

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.

Headline News

Wed, 27 Mar 2024
Simulations Plus (SLP) Set to Announce Earnings on Wednesday - MarketBeat

Tue, 26 Mar 2024
Simulations Plus (NASDAQ:SLP) Stock Crosses Above Two Hundred Day Moving Average of $40.43 - MarketBeat

Tue, 26 Mar 2024
Tributary Capital Management LLC Acquires Shares of 205,367 Simulations Plus, Inc. (NASDAQ:SLP) - MarketBeat

Wed, 20 Mar 2024
Simulations Plus Announces Second Quarter Fiscal Year 2024 Earnings and Conference Call Date - Business Wire

Thu, 14 Mar 2024
Investing in Simulations Plus (NASDAQ:SLP) five years ago would have delivered you a 110% gain - Yahoo Finance

Wed, 13 Mar 2024
Simulations Plus to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Healthcare - Information Services
Shares Out 20 (M)
Shares Float 16 (M)
Held by Insiders 19 (%)
Held by Institutions 78.6 (%)
Shares Short 1,100 (K)
Shares Short P.Month 1,150 (K)
Stock Financials
EPS 0.52
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 8.63
Profit Margin 17.1 %
Operating Margin 9.3 %
Return on Assets (ttm) 4.3 %
Return on Equity (ttm) 6 %
Qtrly Rev. Growth 21.2 %
Gross Profit (p.s.) 0
Sales Per Share 3.11
EBITDA (p.s.) 0.77
Qtrly Earnings Growth 62.5 %
Operating Cash Flow 17 (M)
Levered Free Cash Flow 15 (M)
Stock Valuations
PE Ratio 78.01
PEG Ratio 4.5
Price to Book value 4.79
Price to Sales 13.29
Price to Cash Flow 47.7
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android